Innate Pharma (IPH) — Capital Reinvestment Ratio
Latest as of June 2024:
0.09x
Innate Pharma (IPH) has a Capital Reinvestment Ratio of 0.09x as of June 2024, meaning it reinvests 0% of its operating cash flow (€3.04 Million) in capital expenditures (€283.00K). See IPH free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.09x
Capex / Operating Cash Flow
Operating Cash Flow
€3.04 Million
EUR
Capital Expenditures
€283.00K
EUR
Data as of
Jun 2024
Most recent filing
Innate Pharma Capital Reinvestment Ratio (2006–2019)
This chart tracks Innate Pharma's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for Innate Pharma (2006–2019)
Year-by-year Capital Reinvestment Ratio for Innate Pharma from 2006 to 2019. For live market cap and broader valuation context, see how much is Innate Pharma worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 1.87x | €34.92 Million | €65.40 Million | ▲ +5163.6% |
| 2015 | 0.04x | €207.91 Million | €7.40 Million | ▲ +43.5% |
| 2011 | 0.02x | €12.99 Million | €322.00K | ▼ -98.8% |
| 2006 | 2.09x | €360.00K | €752.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow